Jeongsook Kim

Ms. Jeongsook Kim

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 June 2025 in Molecular Nutrition & Food Research
Verified
Journal Article
Open access
JKJeongsook Kim
Jeongsook Kim
KKKwan‐Woo Kim
Kwan‐Woo Kim
JJJin‐Kyu Jang
Jin‐Kyu Jang
MKMyoung Jin Kim
Myoung Jin Kim
Akila Dushyantha CoorayAkila Dushyantha Cooray
Akila Dushyantha Cooray
Dae Young LeeDae Young Lee
Dae Young Lee
Helicobacter pylori is a Gram‐negative, microaerophilic bacterium that colonizes the human stomach, causing gastritis, gastric ulcers, and gastric cancer. This study investigated the anti‐Helicobacter and anti‐inflammatory effects of Curcuma longa extract (CLE) as a potential treatment for H. pylori infection.Ultra‐high performance liquid chromatography quadrupole time‐of‐flight mass spectrometry (UPLC‐Q‐TOF/MS) analysis identified 18 chemical compounds in CLE, with curcumin, bisdemethoxycurcumin, and bisacurone as major active components. In vitro experiments demonstrated that CLE completely inhibited the growth of H. pylori Sydney strain 1 (SS1) in a dose‐dependent manner and exhibited synergistic effects when combined with amoxicillin. In a mouse model infected with H. pylori SS1 showed that oral administration of CLE for 4 weeks effectively eradicated H. pylori from the stomach without causing toxicity, as evidenced by the CLO test and reduced levels of H. pylori‐associated genes. Furthermore, CLE attenuated inflammatory cell infiltration in the gastric mucosa of infected mice and significantly reduced the expression of proinflammatory cytokines and matrix metalloproteinases in H. pylori‐infected AGS cells, a human gastric cancer cell line.These findings suggest that CLE is a promising candidate for the treatment of H. pylori infection, exhibiting potent antibacterial and anti‐inflammatory properties.

12 March 2025 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
NRNirujan Beno Ramesh
Nirujan Beno Ramesh
JKJeongsook Kim
Jeongsook Kim
EBEun bok Baek
Eun bok Baek
KKKyungmi Kim
Kyungmi Kim
NJNishani Jayathilake
Nishani Jayathilake
KLKyu Pil Lee
Kyu Pil Lee
Background: Lower urinary tract symptoms (LUTS) due to prostate hyperplasia are the most frequent urological symptoms in elderly men. Current pharmacological treatments for LUTS and benign prostatic hyperplasia (BPH) are widely used in clinical practice; however, adverse effects associated with these drugs have been reported for sexual dysfunction and orthostatic hypotension. Prunella vulgaris (PV) is a medicinal herb that has a long history of use. This study aimed to address this gap by investigating the relaxant activity of PV extract (PVE) on rat prostate smooth muscle ex vivo and evaluating intravesical cystometry for its potential. Methods and Results: Ten male Sprague Dawley (SD) rats were used to study the relaxant efficacy of PVE and its constituents in isometric contraction ex vivo. Thirty-six SD rats were randomly assigned to six groups of six animals (n = 6) and administered testosterone propionate (TP; 3 mg/kg) daily for 4 weeks to induce BPH. Groups of BPH rats were treated with or without PVE (30, 60, or 90 mg/kg) via oral gavage. At the end of the experiments, the animals were subjected to intravesical pressure under urethane anesthesia. After successful cystometric recording, rats were euthanized with carbon dioxide. Prostate and bladder tissues were harvested and processed for histological and biochemical analysis. The results demonstrated that PVE exerted relaxant effects on prostatic smooth muscle in a concentration-dependent manner, mediated by nitric oxide and potassium channels, without antagonizing adrenergic receptors. Additionally, intravesical cystometry in SD rats treated with oral gavage of PVE for 4 weeks showed a significant improvement in voiding abnormalities. Conclusions: These findings suggest the potential of PV and its compounds as a therapeutic strategy to improve LUTS associated with BPH.

3 July 2026 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
JKJeongsook Kim
Jeongsook Kim
JSJun-Yeop Song
Jun-Yeop Song
KKKyungmi Kim
Kyungmi Kim
SKSANG-YOON KIM
SANG-YOON KIM
JKJae-Yong Kim
Jae-Yong Kim
KLKyu Pil Lee
Kyu Pil Lee
Background: Bladder dysfunction is a complicated condition that substantially impairs quality of life for both men and women. Due to the adverse effects and limited efficacy of current therapies, new strategies must be rapidly developed. Female bladder dysfunction arises from multifaceted etiologies distinct from the predominantly male benign prostatic hyperplasia (BPH) that is the focus of existing drug development. In this study, we investigated the therapeutic potential of Quisqualis indica extract (QIE), a traditional medicinal herb that attenuates BPH-induced lower urinary symptoms (LUTS), to elucidate its underlying mechanisms in a female bladder dysfunction model. Methods and Results: A bladder dysfunction model was established by inducing partial bladder outlet obstruction (pBOO) in female Sprague Dawley rats, followed by the oral administration of QIE for 7 weeks. Voiding pattern analysis and cystometry were conducted to evaluate indicators such as voiding frequency, voiding volume, and intravesical pressure. Histological analysis of excised bladder tissue quantified smooth muscle hypertrophy and collagen deposition. Gene expression profiling of inflammatory cytokines and fibrosis-related markers within the bladder tissue was performed to assess tissue remodeling. Furthermore, pharmacological contraction studies examined the direct effects of QIE on detrusor muscle responsiveness to muscarinic and purinergic agonists. QIE administration significantly improved the elevated voiding pressure and abnormal inter-contraction intervals observed in the pBOO rats, restoring normal voiding patterns. Histological examination revealed a marked decrease in muscle hypertrophy and collagen deposition. Expression levels of pro-inflammatory cytokines (TNFα, IL-1β) and fibrosis-associated genes (TGF-β, α-SMA) were downregulated. Pharmacological contraction assays demonstrated that QIE attenuated the hypercontractile response of bladder smooth muscle to a muscarinic agonist, with concurrent reduced expression of muscarinic receptors (M2, M3) at the mRNA level. Conclusions:QIE ameliorates key aspects of bladder dysfunction, voiding abnormalities, inflammation, fibrosis, and hypercontractility by modulating muscarinic receptor signaling and fibrotic pathways. This study suggests that QIE warrants further investigation as a natural product-based therapeutic candidate for female bladder dysfunction.